Immuneering reports Q1 2026 financial results and provides pipeline update

Immuneering (NASDAQ:IMRX), a clinical-stage oncology company developing innovative medicines targeting the MAPK pathway, reported its first-quarter 2026 financial results and provided a corporate update.

As of March 31, 2026, the company held $198.6 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2029.

First-quarter research and development expenses were $10.6 million, contributing to a net loss of $13.5 million, or $0.21 per share.

In its lead program, Immuneering announced that the pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer is now recruiting, with first patient dosing expected by mid-2026.

Additionally, new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus mGnP will be presented at the upcoming ASCO 2026 Annual Meeting.

Immuneering (IMRX) Reports Q1 2026 Results with $198.6M Cash Runway into 2029, Advances Phase 3 MAPKeeper 301 Trial.